Skip to content

Inspection prep notes · Laboratory

Stability programs and expiration dating

Also called: stability program, stability testing, expiration date

FDA looks less at whether a stability program exists on paper than at whether the labeled expiration date is supported by actual stability data and testing continues as the program requires. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1Stability data were not adequate to support the expiration date

Your QU also failed to ensure that adequate stability data supported the expiry of your drug products.

FDA Warning Letter · Zhejiang Gaorong Cosmetic Co., Ltd. · 2026-10-20

An adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date.

FDA 483 · Glenmark Pharmaceuticals Inc USA · 2026-11-13 · View document

2Stability-indicating methods were not in place

Your firm has not established stability indicating methods for the OTC (b)(4) drug products you distribute to the U.S. market.

FDA Warning Letter · K.C. Pharmaceuticals, Inc. · 2026-08-18 · View document

The analytical method used for testing stability samples is not stability indicating and cannot identify degradation products.

FDA 483 · SNJ Labs Private Ltd. · 2026-08-05 · View document

3Annual stability batches required by procedure were not placed

Specifically, Based on SOP-003041575, “Stability Program,” at least [redacted] batch per year is required to be placed on stability under long-term conditions through the product shelf life. However, no annual stability batches were placed for [redacted] Tablets. [redacted] mg, representing batches manufactured in 2024.

FDA 483 · Mylan Laboratories Limited · 2026-10-19 · View document

Additionally, your firm's stability management procedure requires that at least one commercial batch be placed on stability annually; however, your firm does not follow this adequately.

FDA 483 · Shimoga Chemicals · 2026-10-23 · View document

4Stability testing was not performed at the planned time points

Specifically, your firm fails to follow SOP GL-059, Stability Program, effective date 10/23/2025, in that stability samples are not consistently tested within their respective testing windows.

FDA 483 · Granules Pharmaceuticals Inc. · 2026-10-23 · View document

Although it appears one batch was placed on stability for years 2021, 2022, and 2023, your firm only completed long-term stability testing to 6 months for these batches.

FDA 483 · Shimoga Chemicals · 2026-10-23 · View document

5Temperature and humidity in stability chambers were not controlled

Additionally, your sample storage chambers were observed to be powered off, and out-of-specification for temperature and/or humidity when powered on.

FDA Warning Letter · Shoolin Pharma Chem LLP · 2026-09-01

Additionally, stability chambers used in the study for accelerated and real-time conditions were not controlled for relative humidity.

FDA 483 · Laboratoires Anios · 2026-10-26

Questions to check against your procedures

  1. Is each labeled expiration date supported by stability data, and does the quality unit confirm it?
  2. Is an adequate number of batches tested to determine the expiration date, and are the records maintained?
  3. Are the analytical methods used for stability samples stability-indicating and able to identify degradation products?
  4. Is a commercial batch placed on stability every year as the procedure requires?
  5. Are stability samples tested within their testing windows, and is long-term testing completed through the last planned time point?
  6. Are stability chambers kept running, with temperature and relative humidity controlled within specification?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.